Literature DB >> 10355218

Clinical experience with oral ketamine.

M C Enarson1, H Hays, M A Woodroffe.   

Abstract

Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist used recently for analgesia in patients with chronic pain. Twenty one patients with chronic neuropathic pain were treated with oral ketamine starting at a divided dose of 100 mg/day and titrating upwards by 40 mg/day until efficacy was reached, or until side effects became limiting. A retrospective chart review was conducted to evaluate the analgesic efficacy and side effects of the treatment. Nine patients discontinued ketamine because of intolerable side effects, four patients experienced few or no side effects but had no discernible benefit, four others had equivocal responses. Four patients have continued oral ketamine for long periods. One patient has had no significant benefit or side effects but continues to use ketamine 500 mg/day and three people have used doses ranging from 100-240 mg day for over 1 year duration and have reported improvements in pain and decreased use of analgesics. The analgesic benefits of ketamine appeared to be most pronounced in, but not limited to, patients with pain histories of less than 5 years.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10355218     DOI: 10.1016/s0885-3924(99)00011-1

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  11 in total

Review 1.  Glutamate receptors and nociception: implications for the drug treatment of pain.

Authors:  M E Fundytus
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

Review 2.  Pharmacologic treatment of neuropathic pain.

Authors:  M S Wallace
Journal:  Curr Pain Headache Rep       Date:  2001-04

Review 3.  Oral ketamine in the palliative care setting: a review of the literature and case report of a patient with neurofibromatosis type 1 and glomus tumor-associated complex regional pain syndrome.

Authors:  Eliezer Soto; Douglas R Stewart; Andrew J Mannes; Sarah L Ruppert; Karen Baker; Daniel Zlott; Daniel Handel; Ann M Berger
Journal:  Am J Hosp Palliat Care       Date:  2011-07-29       Impact factor: 2.500

4.  Oral ketamine analgesia in chronic pain and problematic rise in blood pressure.

Authors:  Oliver van Hecke; Bruce Guthrie
Journal:  BMJ Case Rep       Date:  2014-11-25

Review 5.  Advances in cancer pain management.

Authors:  F J McDonnell; J W Sloan; S R Hamann
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

Review 6.  Translational pain research: achievements and challenges.

Authors:  Jianren Mao
Journal:  J Pain       Date:  2009-07-22       Impact factor: 5.820

7.  Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: Preliminary findings from a three-way randomized, crossover study.

Authors:  Chui Chong; Stephan A Schug; Madhu Page-Sharp; Barry Jenkins; Kenneth F Ilett
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

8.  Treatment considerations in neuropathic pain.

Authors:  Raphael J Leo
Journal:  Curr Treat Options Neurol       Date:  2006-09       Impact factor: 3.972

Review 9.  Advances in cancer pain management.

Authors:  F J McDonnell; J W Sloan; S R Hamann
Journal:  Curr Pain Headache Rep       Date:  2001-06

10.  Oral ketamine for phantom limb pain: An option for challenging cases.

Authors:  Sukanya Mitra; Sunita Kazal
Journal:  Indian J Anaesth       Date:  2015-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.